Noel W Clarke
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Hoyle A, Aebersold D, Jones R, Matheson D, Millman R, Mason M, Ritchie A, Russell M, Douis H, Parmar M, Sydes M, Clarke N, Gillessen Sommer S, Ingleby F, Ali A, James N, Cook A, Parker C, de Bono J, Attard G, Chowdhury S, Cross W, Dearnaley D, Brawley C, Gilson C, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol 2019; 76:719-728.
23.08.2019Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
23.08.2019Eur Urol 2019; 76:719-728
Hoyle Alex P, Aebersold Daniel M, Jones Rob J, Matheson David, Millman Robin, Mason Malcolm D, Ritchie Alastair W S, Russell Martin, Douis Hassan, Parmar Mahesh K B, Sydes Matthew R, Clarke Noel W, Gillessen Sommer Silke, Ingleby Fiona, Ali Adnan, James Nicholas D, Cook Adrian, Parker Christopher C, de Bono Johann S, Attard Gerhardt, Chowdhury Simon, Cross William R, Dearnaley David P, Brawley Christopher D, Gilson Clare, STAMPEDE Investigators
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols
Schiavone F, Langley R, Kaplan R, Parker C, Attard G, Clarke N, Gillessen Sommer S, James N, Maughan T, Sydes M, Parmar M, Hudson F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, Brown L, Gilson C, Pugh C, Atako N, past and present members of the STAMPEDE and FOCUS4 Trial Management Group. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials 2019; 20:264.
29.05.2019This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols
29.05.2019Trials 2019; 20:264
Schiavone Francesca, Langley Ruth, Kaplan Richard S, Parker Chris, Attard Gert, Clarke Noel W, Gillessen Sommer Silke, James Nicholas D, Maughan Tim, Sydes Matthew R, Parmar Mahesh, Hudson Fleur, Bathia Riya, Letchemanan Krishna, Masters Lindsey, Amos Claire, Bara Anna, Brown Louise, Gilson Clare, Pugh Cheryl, Atako Nafisah, past and present members of the STAMPEDE and FOCUS4 Trial Management Group
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, Jonnada S, Gannon M, Gale J, Eswar C, Douis H, Din O, Birtle A, Bahl A, Khaksar S, Lester J, O'Sullivan J, Sydes M, Parmar M, Tran A, Srihari N, Sheehan D, Pudney D, Pedley I, Parikh O, Alonzi R, Amos C, Thalmann G, Chowdhury S, Attard G, Ritchie A, Ali A, Hoyle A, Clarke N, Brawley C, James N, Cross W, Dearnaley D, Gillessen Sommer S, Russell J, Millman R, Matheson D, Mason M, Malik Z, Langley R, Jones R, Gilson C, Parker C. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392:2353-2366.
21.10.2018Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
21.10.2018Lancet 2018; 392:2353-2366
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, Jonnada Sai, Gannon Melissa R, Gale Joanna, Eswar Chinnamani, Douis Hassan, Din Omar, Birtle Alison, Bahl Amit, Khaksar Sara, Lester Jason F, O'Sullivan Joe M, Sydes Matthew R, Parmar Mahesh K B, Tran Anna T H, Srihari Narayanan Nair, Sheehan Denise J, Pudney Delia M, Pedley Ian D, Parikh Omi A, Alonzi Roberto, Amos Claire L, Thalmann George N, Chowdhury Simon, Attard Gerhardt, Ritchie Alastair W S, Ali Adnan, Hoyle Alex P, Clarke Noel W, Brawley Christopher D, James Nicholas D, Cross William, Dearnaley David P, Gillessen Sommer Silke, Russell J Martin, Millman Robin, Matheson David, Mason Malcolm D, Malik Zafar I, Langley Ruth E, Jones Robert J, Gilson Clare, Parker Christopher C
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
STAMPEDE Investigators, McPhail N, McKinna F, Malik Z, Lester J, Hoskin P, Hingorani M, Gray E, Gale J, Ferguson C, Chakraborti P, Money-Kyrle J, O'Sullivan J, Sydes M, Parmar M, Zarkar A, Wylie J, Wagstaff J, Thomas C, Srihari N, Robinson A, Protheroe A, Parikh O, Brock S, Bowen J, Matheson D, Jones R, Gilson C, Amos C, Ritchie A, Dearnaley D, Mason M, Clarke N, Spears M, de Bono J, Millman R, Attard G, Birtle A, Aung S, Adab F, Brawley C, Berthold D, Russell J, Parker C, Gillessen Sommer S, Cross W, Chowdhury S, James N. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-351.
03.06.2017Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
03.06.2017N Engl J Med 2017; 377:338-351
STAMPEDE Investigators, McPhail Neil, McKinna Fiona, Malik Zafar I, Lester Jason F, Hoskin Peter J, Hingorani Mohan, Gray Emma, Gale Joanna, Ferguson Catherine, Chakraborti Prabir, Money-Kyrle Julian, O'Sullivan Joe, Sydes Matthew R, Parmar Mahesh K B, Zarkar Anjali, Wylie James, Wagstaff John, Thomas Carys, Srihari Narayanan N, Robinson Angus, Protheroe Andrew, Parikh Omi, Brock Susannah, Bowen Jo, Matheson David, Jones Rob J, Gilson Clare, Amos Claire L, Ritchie Alastair W S, Dearnaley David P, Mason Malcolm D, Clarke Noel W, Spears Melissa R, de Bono Johann S, Millman Robin, Attard Gerhardt, Birtle Alison J, Aung San, Adab Fawzi, Brawley Chris, Berthold Dominik R, Russell J Martin, Parker Christopher C, Gillessen Sommer Silke, Cross William R, Chowdhury Simon, James Nicholas D
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial
James N, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar M, Sydes M, Engeler D, Birtle A, Spears M, Clarke N, Dearnaley D, Mason M, Parker C, Ritchie A, Russell J, Schiavone F, Attard G, de Bono J. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol 2016; 2:348-57.
01.03.2016Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial
01.03.2016JAMA Oncol 2016; 2:348-57
James Nicholas D, Elliott Tony, Matheson David, O'Sullivan Joe, Pudney Delia, Srihari Narayanan, Wallace Jan, Barber Jim, Syndikus Isabel, Parmar Mahesh K B, Sydes Matthew R, Engeler Daniel, Birtle Alison, Spears Melissa R, Clarke Noel W, Dearnaley David P, Mason Malcolm D, Parker Christopher C, Ritchie Alastair W S, Russell J Martin, Schiavone Francesca, Attard Gerhardt, de Bono Johann S